<DOC>
	<DOCNO>NCT02036775</DOCNO>
	<brief_summary>To characterise pharmacokinetics assess relative bioavailability two new oral formulation ambroxol hydrochloride Lasolvan® prolonged-release hard capsule 75 mg Lasolvan® effervescent tablet 60 mg compare Lasolvan® tablet 30 mg</brief_summary>
	<brief_title>Pharmacokinetics Bioavailability Study Lasolvan Hard Capsules Effervescent Tablets Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ambroxol</mesh_term>
	<criteria>Inclusion criterion : Given write informed consent participation study . Male female subject age 1845 , inclusive . Body mass index Quetelet 18.50 24.99 kg/m2 , inclusive . Judged investigator good health document medical history , physical examination ( include may limited evaluation cardiovascular , gastrointestinal , renal system ) , vital sign assessment , 12lead electrocardiogram ( ECG ) , clinical laboratory assessment , general observation . Any abnormality outside normal range clinical testing ( laboratory test , ECG , vital sign ) repeat discretion investigator judge clinically significant study participation . Female subject childbearing potential agree use doublebarrier contraception study . If female postmenopausal ( menses least 1 year ) surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) exempt requirement . In case use oral contraceptive , withdraw least 2 month study . Male subject agree use effective contraception study ( barrier contraceptive method ) . Exclusion criterion : Known hypersensitivity ambroxol hydrochloride , constituent test reference product . Known rare hereditary condition ( StevensJohnson syndrome , toxic epidermal necrolysis , galactose intolerance , Lapplactase deficiency , glucosegalactose malabsorption ) . Pregnancy breastfeed . Chronic hepatic , renal , cardiovascular , respiratory , gastrointestinal , neuroendocrine disease blood disorder . Positive result blood test current infection ( HIV , syphilis , hepatitis B C ) . Surgery gastrointestinal tract ( except appendectomy ) within past 8 week . Acute infection occur within 4 week inclusion study . Regular drug intake within 2 week inclusion study . Intake systemic drug know affect cytochrome P450 system ( induce inhibit ) within 4 week inclusion study . Blood donation ( great equal 450 ml ) within 2 month inclusion study . Alcohol intake great equal 10 unit alcohol per week ( 1 unit alcohol equal one 50 ml single measure whisky ( ABV alcohol volume 40 % ) , 0.5 litre beer ( ABV 5 % ) , 200 ml glass red wine ( ABV 12 % ) history alcohol abuse , narcomania , drug abuse . A positive urine drug test ( cannabis , benzodiazepine , barbiturate , opiate , cocaine , amphetamine ) screen first dose study period . A positive alcohol test screening first dose study period Participation another phase I clinical study within 3 month inclusion study . Known lactose intolerance . Known phenylketonuria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>